• Biote first-quarter 2026 earnings call drew Chief Executive Officer Bret Christensen, Chief Financial Officer Bob Peterson, Investor Relations lead Szymon Serowiecki, analysts, investors.
• Revenue fell 8.3% to USD 44.9 million as procedure revenue dropped 13.2% to USD 31.3 million, including USD 1.7 million hit from voluntary recall of certain hormone pellets shipped by Asteria Health; management flagged continued headwind into second quarter.
• Gross margin narrowed to 68.9% from 74.3% on USD 1.1 million incremental recall costs; Asteria produced about 30% of shipped pellets versus over 50% in fourth-quarter 2025, with supply continuity targeted by end of second quarter as second shift ramps.
• Adjusted EBITDA declined to USD 8.7 million, margin 19.4%; net income was USD 2.7 million, EPS USD 0.06, aided by USD 2.1 million gain tied to earn-out liability revaluation.
• Full-year guidance maintained for revenue above USD 190 million, adjusted EBITDA above USD 38 million; management expects procedure revenue to return to growth in second half on normalized inventory, pent-up demand, sales force expansion to about 120 reps, attrition described as stable with no meaningful recall-driven increase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. biote Corporation published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.